Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific RNA Based Therapeutic Market, by Type
1.4.2 Asia Pacific RNA Based Therapeutic Market, by Application
1.4.3 Asia Pacific RNA Based Therapeutic Market, by End User
1.4.4 Asia Pacific RNA Based Therapeutic Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2022, Jan) Leading Players
Chapter 4. Asia Pacific RNA Based Therapeutic Market by Type
4.1 Asia Pacific RNA Antisense Market by Country
4.2 Asia Pacific RNA Interference (RNAi) Market by Country
Chapter 5. Asia Pacific RNA Based Therapeutic Market by Application
5.1 Asia Pacific Genetic disorders Market by Country
5.2 Asia Pacific Auto immune disorders Market by Country
Chapter 6. Asia Pacific RNA Based Therapeutic Market by End User
6.1 Asia Pacific Research Institutes Market by Country
6.2 Asia Pacific Hospitals & Clinics Market by Country
Chapter 7. Asia Pacific RNA Based Therapeutic Market by Country
7.1 China RNA Based Therapeutic Market
7.1.1 China RNA Based Therapeutic Market by Type
7.1.2 China RNA Based Therapeutic Market by Application
7.1.3 China RNA Based Therapeutic Market by End User
7.2 Japan RNA Based Therapeutic Market
7.2.1 Japan RNA Based Therapeutic Market by Type
7.2.2 Japan RNA Based Therapeutic Market by Application
7.2.3 Japan RNA Based Therapeutic Market by End User
7.3 India RNA Based Therapeutic Market
7.3.1 India RNA Based Therapeutic Market by Type
7.3.2 India RNA Based Therapeutic Market by Application
7.3.3 India RNA Based Therapeutic Market by End User
7.4 South Korea RNA Based Therapeutic Market
7.4.1 South Korea RNA Based Therapeutic Market by Type
7.4.2 South Korea RNA Based Therapeutic Market by Application
7.4.3 South Korea RNA Based Therapeutic Market by End User
7.5 Singapore RNA Based Therapeutic Market
7.5.1 Singapore RNA Based Therapeutic Market by Type
7.5.2 Singapore RNA Based Therapeutic Market by Application
7.5.3 Singapore RNA Based Therapeutic Market by End User
7.6 Malaysia RNA Based Therapeutic Market
7.6.1 Malaysia RNA Based Therapeutic Market by Type
7.6.2 Malaysia RNA Based Therapeutic Market by Application
7.6.3 Malaysia RNA Based Therapeutic Market by End User
7.7 Rest of Asia Pacific RNA Based Therapeutic Market
7.7.1 Rest of Asia Pacific RNA Based Therapeutic Market by Type
7.7.2 Rest of Asia Pacific RNA Based Therapeutic Market by Application
7.7.3 Rest of Asia Pacific RNA Based Therapeutic Market by End User
Chapter 8. Company Profiles
8.1 Arbutus Biopharma Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.4.2 Acquisitions, Mergers and Joint Ventures:
8.2 Arrowhead Pharmaceuticals, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Benitec Biopharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.4 Alnylam Pharmaceuticals, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expense
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Approvals and Trials:
8.5 Sanofi S.A. (Sanofi Genzyme)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Biogen, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.7 Gradalis, Inc.
8.7.1 Company Overview
8.8 Ionis Pharmaceuticals, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.9 Sarepta Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.9.4 Recent strategies and developments:
8.9.4.1 Partnerships, Collaborations, and Agreements:
8.10. Silence Therapeutics Plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
Unique Offerings 